In Brief: U.K. may consolidate AER system, New York restricts DXM sales, Actavis divests oral contraceptives, homeopathic earache products warned
This article was originally published in The Tan Sheet
Executive Summary
U.K. eyes consolidating AER system; NY restricts DXM sales; Actavis divests oral contraceptives; ScriptPro simplifies NPLEx; firms warned for homeopathic earache products; tainted supplement recalls; CRN seeks more time for medical food comments; and vitamin K2 gains in popularity.
You may also be interested in...
In Brief: Clearblue estimates weeks, Barry Meltzer dies, P&G eliminating phthalates and triclosan, NPLEx adds Delaware
P&G Clearblue pregnancy test estimates week of conception; AHPA co-founder Meltzer dies; P&G to eliminate phthalates, triclosan; CSPI, Aloe Science Council square off; Delaware joins NPLEx; IADSA focuses on supplement safety guidelines; Pharmavite expands Alabama facility.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.